The Weekly Mind Reader: Ghrelin, Anxiety, and Disordered Eating

by Liz Neporent
May 5, 2023 at 9:05 AM UTC

minor ear anomalies are more common in people with depressive order.

The discovery of the hormone ghrelin in 1999 revolutionized the science of appetite, especially as it relates to disordered eating patterns. More recently, it’s been implicated in the regulation of anxiety

Ghrelin, Anxiety, and ARFID

A new study in The Journal of Clinical Psychiatry neatly put these two theories together by examining ghrelin’s relationship to anxiety in people with avoidant/restrictive food intake disorder, or ARFID.

The Harvard Medical School-led trial recruited 80 young participants who met the full or subthreshold for ARFID. Subjects were screened with a variety of assessments to determine their anxiety levels. They also had their blood drawn to measure their ghrelin levels. After three months, the scientists repeated all tests for comparison.

Overall, lower levels of ghrelin were associated with higher levels of anxiety, particularly in those with ARFID. There was a moderate but significant correlation for all measures of anxiety. Even after taking into account body mass index (BMI) and other factors, the link between ghrelin levels and anxiety remained significant for all 69 subjects in the group that met the full threshold criteria for ARFID. 

In a randomly selected group of participants, ghrelin levels predicted anxiety and obsessive-compulsive disorders with 96 percent accuracy. A diagnosis of either depressive and bipolar disorders accurately correlated with hormone levels 94 percent of the time. For all other categories of mental health diagnoses in the group, the association was 100 percent accurate.

The reason for the inverse relationship? The authors aren’t sure. It could be that a smaller release of ghrelin led to higher anxiety in individuals with ARFID. Or the opposite: ARFID might have caused a drop in ghrelin, which then turned up the dial on anxiety.

Whichever theory is correct, the authors said the discovery could prove useful.

“The confluence of lower ghrelin among individuals with ARFID whose anxiety is high raises the intriguing possibility that interventions targeting ghrelin pathways could be especially beneficial to this group,” they wrote.

In Other Psychiatry and Neurology News This Week 

Tweet of the Week

May is mental health awareness month. This tweet serves as a great reminder to treat people with empathy. You never know what someone is going through. We should also note, Dani Donovan will be the keynote speaker at CME Institute’s Live Meeting: Emerging Perspectives in Psychiatry, June 24 in New York City, sharing her personal perspective on ADHD and patient advocacy. 

New at CME Institute

Click to earn free accredited CME credit.

Live CME Meeting: Emerging Perspectives in Psychiatry | June 24 in NYC

Tweetorial: Analyzing Two Schizophrenia Case Reports

Original Research

A Pilot Study of High-Frequency Transcranial Magnetic Stimulation for Bipolar Depression

In this study of patients with bipolar depression, 87.1% reached response and 74.2% reached remission with 6 weeks of rTMS.

Scott T. Aaronson and others

Letter to the Editor

Geriatric Depression: What Clinicians Need to Know

The authors discuss what clinicians should be aware of when caring for elderly patients with depression.

Ahmed Naguy and others